News

Anti-MEK-PI3K Drug Combination Reduces Lesions in Solid Tumors

Publish date: April 11, 2011

 

FROM THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH

"I hope I am wrong," he said.

Genentech sponsored the study. Dr. Bendell said she had no relevant financial disclosures. Dr. Der disclosed relationships with GlaxoSmithKline, Millipore, Bristol-Myers Squibb, and Sanofi-Aventis.

Pages

Recommended Reading

New Formula Gauges Disease-Free Colorectal Survival
MDedge Internal Medicine
Higher Opioid Doses More Likely to Lead to Unintentional Overdose
MDedge Internal Medicine
NCCN Tightens Active Surveillance in Prostate Cancer Guidelines
MDedge Internal Medicine
Endobronchial Dysplasia Could Be Marker for Lung Cancer Chemoprevention
MDedge Internal Medicine
Fewer Than Half of Ovarian Cancer Patients Get Care Consistent with NCCN Guidelines
MDedge Internal Medicine
FDA Approves First Drug for Medullary Thyroid Cancer
MDedge Internal Medicine
Study Suggests Wider Role for Neoadjuvant Chemo in Ovarian Cancer
MDedge Internal Medicine
Adherence to Treatment Guidelines Varies Widely in Colon Cancer
MDedge Internal Medicine
Discordant Afinitor Trial Results Prompt FDA Panel Review
MDedge Internal Medicine
Thin vs. Thick Melanomas: Both Carry Same SLN Involvement Risk
MDedge Internal Medicine